We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment With TNF Blockade, Infliximab, in Patients With Myositis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00443222
First Posted: March 5, 2007
Last Update Posted: March 5, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Schering-Plough
Medical Research Council
Information provided by:
Karolinska Institutet
  Purpose

This is a 4 month open trial with TNF-blockade using infliximab (an antibody that blocks TNF) in adult patients with chronic myositis (polymyositis, dermatomyositis, inclusion body myositis) who have persisting muscle weakness and inflammatory active disease despite adequate treatment with immunosuppressives either currently or previously.

Infliximab is given as infusions, 5 mg/kg body weight, these infusions are repeated after 2, 6 and 14 weeks. The study involves 15 adult patients.

Primary outcome measure is muscle function assessed by muscle function index score.

Other outcome measures are Myositis Disease Activity core set: Patient’s global assessment and physicians global assessment on visual analogue scales (VAS). Manual muscle test, Health assessment questionnaire (HAQ), serum levels of CPK, LD and extra muscular disease activity score. Muscle biopsy, Magnetic resonance imaging (MRI) of thigh muscles and Health related Quality of life, measured by SF-36.


Condition Intervention Phase
Refractory Myositis Drug: Infliximab Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies

Resource links provided by NLM:


Further study details as provided by Karolinska Institutet:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients.
  • Persisting muscle weakness defined as ≤ 80% of muscle strength as measured by functional index of myositis
  • Signs of disease activity defined as muscle edema observed by magnetic resonance imaging (MRI) or creatine kinase (CK) elevation, or inflammatory cell infiltrates on muscle biopsy, and failure to respond to treatment with glucocorticoids for a minimum of six months in combination with azathioprine or methotrexate.

Exclusion Criteria:

  • Pregnant women, nursing mothers or a planned pregnancy within one and a half years of enrolment.
  • Prior administration of infliximab or any other therapeutic agent targeted at reducing TNF (e.g., Etanercept, pentoxifylline, thalidomide or anti-CD4+ antibody) within the previous six months.
  • A history of known allergies to murine proteins.
  • Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months. Less serious infections in the previous 3 months, such as acute upper respiratory tract infection (colds) or uncomplicated urinary tract infection (colds) or uncomplicated urinary tract infection need not to considered exclusions at the discretion of the treating physician.
  • History of opportunistic infections such as herpes zoster within 2 months of screening. Evidence of active CMV, active pneumocystis carinii, drug resistant atypical mycobacterium, etc.
  • Documented HIV infection.
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic or cerebral disease.
  • Any currently known malignancy or pre-malignant lesions or any history of malignancy within the past five years.
  • Patients with alcoholism, alcoholic liver disease, or other chronic liver disease.
  • Patients with a positive PPD and chest X-Ray suggestive of active TB or a previous exposure to TB.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00443222


Sponsors and Collaborators
Karolinska Institutet
Schering-Plough
Medical Research Council
Investigators
Principal Investigator: Ingrid E Lundberg, MD, PhD Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
  More Information

ClinicalTrials.gov Identifier: NCT00443222     History of Changes
Other Study ID Numbers: Remicade myositis
First Submitted: March 2, 2007
First Posted: March 5, 2007
Last Update Posted: March 5, 2007
Last Verified: March 2007

Keywords provided by Karolinska Institutet:
infliximab
polymyositis
dermatomyositis
inclusion body myositis

Additional relevant MeSH terms:
Myositis
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Infliximab
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents